RP-HPLC法测定醋青皮配方颗粒中橙皮苷的含量

目的 :建立醋青皮配方颗粒中橙皮苷含量的测定方法。 方法 :运用正交试验优化样品处理的提取条件,采用高效液相色谱法检测橙皮苷含量,色谱柱为Shim-pack VP-ODS柱(4.6 mm×250 mm,5 μm);流动相为甲醇-0.1%磷酸(35 ∶65);流速1 mL ·min^-1;检测波长284 nm。 结果 :橙皮苷在0.112 0~1.120 μg呈良好的线性关系 (r=0.999 9),平均回收率为102.63%,RSD为1.24%。 结论 :该法简便可行、快速,可用于醋青皮配方颗粒的质量控制。     

鼻咽癌肝肺转移的放疗加中药治疗探讨

目的 :观察放疗加中药治疗鼻咽癌肝肺转移的疗效。方法 :90例患者随机分成对照组 45例和治疗组 45例。治疗组采用放疗加中药法 ,对照组采用单纯放疗法。结果 :治疗组鼻咽癌肝肺转移有效率为 82 .2 % ,肝转移的平均生存期12 .0 5月 ,肺转移为 14 .2 6月 ,肝肺均转移为 5 .96月。对照组有效率为 5 7.8% ,肝转移的平均生存期 8.38月 ,肺转移为 9.30月 ,肝肺均转移为 5 .5 3月。结论 :对鼻咽癌肝肺转移的放疗配合应用中药治疗能更好缓解症状 ,控制肿瘤 ,减轻反应 ,延长患者生存期。     

超声下两种颈内静脉置管法的比较

目的 超声下比较两种路径颈内静脉置管方法的准确性及并发症的发生率,寻找更安全、可靠的颈内静脉穿刺路径。方法 选择需行颈内静脉穿刺患者60例,随机分为传统中路法穿刺组(A组,n=30)与颈内静脉搏动点法穿刺组(B组,n=30)。观察颈总动脉直径(D1)、颈内静脉直径(D2)、颈总动脉和颈内静脉重叠覆盖率、穿刺路径距颈内静脉中心距离(D3)、穿刺路径距颈总动脉外侧距离(D4)及可能触及颈总动脉例数。结果 与A组比较,B组D3较小,差异有统计学意义(P<0.05);B组D4明显大于A组,差异有统计学意义(P<0.05)。结论 颈内静脉搏动点法行颈内静脉穿刺更准确,并发症发生率更低。     

西北寒燥证模型与IL-2、IL-6、INF-γ、TNF-α关系研究

目的 揭示西北寒燥证模型血清中IL-2,IL-6,INF-γ,TNF-α的含量.方法 通过人工气候箱模拟新疆寒燥环境,并作用于小鼠以建立西北寒燥证模型,21 d后眼球取血处死模型动物,测定其外周血中IL-2,IL-6,INF-γ,TNF-α含量的变化.结果 与空白对照组相比,西北寒燥证模型组血清中IL-2,INF-γ含量低于空白对照组,IL-6,TNF-α含量高于空白对照组,但从所测得数据分析无统计学意义.结论 西北寒燥证虽是机体一种整体状态的改变,但并非所有器官组织的功能均存在显著改变,有些尚处于代偿状态,间接提示中医的"证"并不能界定所有的基于现代医学思维和统计方法微观医学指标.     

糖心合剂对2型糖尿病合并心功能不全患者心功能的影响

目的探讨糖心合剂对2型糖尿病合并心功能不全患者心功能的影响。方法将49例2型糖尿病合并心功能不全患者随机分为对照组20例、治疗组29例,对照组采用西药常规治疗(强心剂、利尿剂、血管紧素转换酶抑制剂、β受体阻滞剂及硝酸酯类药物),治疗组在对照组基础上口服糖心合剂4粒,每日3次,共治疗12周。比较两组的临床疗效,心脏超声检测治疗前后左心室收缩末期内径(LVESD)、左心室舒张末期内径(LVEDD)、左室射血分数(EF)、左室短轴缩短率(FS)、E/A值,评价心功能。结果治疗组的临床总有效率为89.65%,对照组为60.00%,治疗组优于对照组(P<0.05);治疗组心功能各项指标均较治疗前明显改善,差异有统计学意义(P<0.05或P<0.01);对照组治疗后EF、FS较前有所好转(P<0.01),治疗组改善程度优于对照组(P<0.05或P<0.01)。结论糖心合剂能够改善2型糖尿病合并心功能不全患者的心功能。     

Amphotericin B: a biological response modifier in targeting against the salvage pathways

Dipyridamole, a nucleoside transport inhibitor which blocks the rescue effect of exogenous nucleosides, is a compound of interest for use in combination with antimetabolites of de novo purine and pyrimidine biosynthesis. This study has provided evidence that the dipyridamole inhibitory effect on nucleoside incorporation varied markedly during the course of cell growth in culture. Human colon cancer HT-29 cells in lag and log phases were highly sensitive to the blocking action of dipyridamole on thymidine incorporation with IC50 values of 0.06 and 0.07 microM respectively. In contrast, stationary phase cells were comparatively insensitive to dipyridamole with an IC50 of 46 microM. Amphotericin B restored the sensitivity of stationary phase cells to dipyridamole, lowering the IC50 value for thymidine incorporation to 0.03 microM. A similar pattern was observed for cytidine incorporation. Amphotericin B also enhanced the growth inhibitory action of dipyridamole in stationary phase cells. The combination of amphotericin B and dipyridamole should be potentially useful in cancer chemotherapy.     

挤出造粒、气流包衣法制备包衣微粒剂.V.去羟肌苷肠溶微粒的制备和药动学研究

用挤出造粒、气流包衣法研制了去羟肌苷肠溶微粒,药物在0.1mol/L盐酸中2h不降解,在pH 6.8磷酸盐缓冲液中10min的释放率达75%以上.Beagle犬体内的药动学研究证明,制得的去羟肌苷肠溶微粒相对生物利用度是去羟肌苷分散片的169%.     

齐墩果酸诱导人结肠癌LoVo细胞凋亡作用研究

目的研究齐墩果酸（oleanolic acid,OA）诱导人结肠癌LoVo细胞株凋亡的机制。方法应用浓度为2.00～32.00 mg&#8226;L 1OA作用于人结肠癌LoVo细胞12～96 h后,采用噻唑蓝（MTT）法检测OA对LoVo细胞的抑制作用,采用流式细胞术、Western blot印迹法等检测细胞周期变化、凋亡及Bcl 2、Bax、p53、Caspase 3蛋白表达,在光镜及电镜下观察细胞形态学变化。结果OA呈时间 剂量依赖性抑制LoVo细胞增殖,能诱导LoVo细胞凋亡及阻滞细胞于G2/M期,OA作用LoVo细胞48 h后,各组的细胞凋亡率为10.32%～14.24%（P＜0.05),并出现Bcl 2蛋白表达抑制, p53、Bax及Caspase 3活性增强。结论OA可以促进人结肠癌LoVo细胞凋亡,其促凋亡机制与抑制Bcl 2表达及促进p53、Bax及Caspase 3表达有关。     

Ⅲ型胶原α链基因mRNA的表达与舌苔形成的关系研究

目的研究Ⅲ型胶原α链基因表达水平与舌苔形成之间的关系。方法应用基因芯片技术和实时荧光定量逆转录-聚合酶链反应（RT-PCR）技术,检测Ⅲ型胶原α链在不同舌苔中的表达水平。结果基因芯片显示,常见舌苔中Ⅲ型胶原α链表达水平差异有统计学意义;实时荧光定量PCR证实从高到低依次为：黄厚苔〉白薄苔〉白厚苔〉无苔〉黄薄苔〉胎儿白薄苔。结论常见舌苔中,Ⅲ型胶原α链表达水平有差异,提示Ⅲ型胶原α链基因表达水平的调控在舌苔形成过程中可能有一定的意义。     

EGFR mutation types and abundance were associated with the overall survival of advanced lung adenocarcinoma patients receiving first-line tyrosine kinase inhibitors

BackgroundEpidermal growth factor receptor tyrosine kinases inhibitors (EGFR-TKIs) are currently recognized as the standard treatment for advanced non-small cell lung cancer (NSCLC) patients with EGFR mutations. Clinically found patients with different EGFR mutational status have different prognosis.MethodsA retrospective cohort study was performed to explore the relationship between EGFR mutations and abundance with patient survival by using patient data from the Affiliated Cancer Hospital of Zhengzhou University between January 2013 and November 2016. All patients involved in the present study had sensitive EGFR mutations [either exon 19 deletion (DEL) or exon 21 L858R] and treated by EGFR-TKIs. They were followed up every three months until lost or dead. Mutation abundance was calculated as the copies of EGFR mutation divided by copies of EGFR locus, and the cut-off values for 19DEL and L858R were 4.9% and 9.5%, respectively.ResultsTotal of 236 patients were included, comprising 116 (49.2%) patients with 19DEL mutation and 120 (50.8%) patients with L858R mutation. The median follow-up duration was 23.2 months (95% CI: 14.9–26.7 months). Overall survival (OS) was significantly longer in patients with 19DEL mutation (20.9 months, 95% CI: 17.7–24.1 months versus 17.0 months, 95% CI: 14.4–19.6 months in patients with L858R; P=0.008) and in patients with high mutation abundance (20.9 months, 95% CI: 18.3–23.5 months versus 13.0 months, 95% CI: 10.3–15.7 months in patients with low mutation abundance; P<0.001). Multivariate Cox regression including age, performance status and tumor stage revealed that longer OS was independently associated with 19DEL mutation (HR: 0.48, 95% CI: 0.39–0.67, P=0.033) and high mutation abundance (HR: 0.62, 95% CI: 0.50–0.79, P=0.027).ConclusionsEGFR mutation types and abundance was associated with the patients’ survival which might be used to predict the efficacy of targeted therapy by EGFR-TKIs.